Tüberküloz Tedavisinde Kullanılan İlaçlara Karşı Direnç Mekanizmaları

Authors

Ali Albay

References

World Health Organization. Global tuberculosis report 2025, World Health Organization, Geneva, 2025.

Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. World Health Organization, Geneva, 2021.

Khosravi NA, Sirous M, Khosravi AD, et al. A narrative review of bedaquiline and delamanid: New arsenals against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. Journal of Clinical Laboratory Analysis; 2024; 38(15-16): p.1-14. doi: 10.1002/jcla.25091.

Kherabi Y, Pedersen OS, Lange C, et al. Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study. The Lancet Regional Health – Europe. 2025; (56): 101380 p. 1-15. doi: 10.1016/j.lanepe.2025.101380

Naidoo K, Perumal R, Ngama SL, et al. Rapid diagnosis of drug-resistant tuberculosis-opportunities and challenges. Pathogens. 2023; Dec 27;13(1):27. p. 1-23. doi: 10.3390/pathogens13010027.

Rossini NO, Dias MVB. Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line drugs. Genetics and Molecular Biology. 2023; 46(1) (Suppl 2) P. 1-17. doi: 10.1590/1678-4685-GMB-2022-026.

Goossens SN, Sampson SL, Rie AV. Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis. Clinical Microbiology Reviews. 2021; 34(1):e00141-20. p. 1-21. doi: 10.1128/CMR.00141-20.

Rukmana A, Gozali C, Erlina L. Mycobacterium tuberculosis Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia. International Journal of Microbiology. 2024; 4: 2024: p. 1-9. doi: 10.1155/2024/203796.

Yang J, Zhang L, Qiao W, et al. Mycobacterium tuberculosis: Pathogenesis and therapeutic targets. MedComm. 2023;4(5)e353. p. 1-39. doi: 10.1002/mco2.353.

Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, current treatment regimens and new drug targets. International Jurnal of Molecular Sciences. 2023 Mar 8; 24(6):5202. p. 1-23. doi: 10.3390/ijms24065202.

Vilcheze C, Jacobs JR WR. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiology Spectrum. 2014 Aug; 2(4): p1-37.doi: 10.1128/microbiolspec.MGM2-0014-2013.

Khawbung JL, Nath D, Chakraborty S. Drug resistant tuberculosis: a review. Comparative Immunology, Microbiology and Infectious Diseases. 2021; 74:101574. P. 1-9. doi: 10.1016/j.cimid.2020.101574.

Nguyen L. Antibiotic resistance mechanisms in M. tuberculosis: an update. Archives of Toxicology. 2016 July; 90(7): p.1585–1604. doi:10.1007/s00204-016-1727-6.

Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics. 2014;3(3), p.317-340. doi:10.3390/antibiotics3030317.

Zhang X, Zhao R, Qi Y, et al. The progress of Mycobacterium

tuberculosis drug targets. Frontiers in Medicine. 2024 Oct 21;(11) :1455715. p. 1-11. doi: 10.3389/fmed.2024.1455715.

Biltekin N, Dülger M. Tüberküloz tedavisinde kullanılan antitüberküloz ilaçlar. Mersin Universitesi Saglık Bilimleri Dergisi. 2023; 16(3): p.525-542 doi: 10.26559/mersinsbd.1213832.

Dookie N, Ngema SL, Perumal R, et al. The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives. Clinical Microbiology Reviews. 2022 Dec 21; 35(4):e0018019. doi: 10.1128/cmr.00180-19.

Khosravi NA, Sirous M, Khosravi AD, et al. A narrative review of bedaquiline and delamanid: new arsenals against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. Journal of Clinical Laboratory Analysis. 2024; 38(15-16):e25091. doi: 10.1002/jcla.25091.

Sonnenkalb L, Carter JJ, Spitaleri A, et al. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. Lancet Microbe. 2023 May; 4(5):e358–e368. doi: 10.1016/S2666-5247(23)00002-2.

Khosravi NA, Khosravi AD, Hashemzadeh M, et al. Investigation of delamanid, bedaquiline,and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran. BMC Microbiology. 2025 Aug 15; 25:509. doi: 10.1186/s12866-025-04213-y.

Hu X, Wu Z, Lei J, et al. BMC Infectious Diseases. Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. 2025 May 12;25(1):689. doi: 10.1186/s12879-025-11067-2.

Nguyen TVA, Nguyen QH, Nguyen TNT, et al. Pretomanid resistance: an update on emergence, mechanisms and relevance for clinical practice. International Journal of Antimicrobial Agents. 2023 Oct;62(4):106953. doi: 10.1016/j.ijantimicag.2023.106953.

Published

November 17, 2026

License

License